Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 0.63 |
| ▸ | GRM5 | P41594 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23680778 | 0.89 | HPGD (0.70) | HPGDGRM5EGFRALDH1A1MGLL | |
| SCHEMBL23680761 | 0.88 | HPGD (0.76) | HPGDGRM5EGFRALDH1A1ADORA2A | |
| SCHEMBL23680746 | 0.87 | HPGD (0.66) | HPGDGRM5ALDH1A1ADORA2AMGLL | |
| SCHEMBL23680759 | 0.86 | HPGD (0.77) | HPGDGRM5MGLL | |
| SCHEMBL23680797 | 0.85 | HPGD (0.66) | HPGDGRM5ALDH1A1ADORA2AMGLL | |
| SCHEMBL23680790 | 0.85 | HPGD (0.71) | HPGDALDH1A1ADORA2AMGLL | |
| SCHEMBL23680729 | 0.84 | HPGD (0.64) | HPGDGRM5ALDH1A1MGLL | |
| SCHEMBL23680707 | 0.84 | HPGD (0.61) | HPGDGRM5ADORA2AMGLL | |
| SCHEMBL23680800 | 0.83 | HPGD (0.63) | HPGDGRM5EGFRALDH1A1MGLL | |
| SCHEMBL23680791 | 0.83 | HPGD (0.74) | HPGDALDH1A1ADORA2AMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345702-B1 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | HPGD 1/4885GRM5 1551/4885EGFR 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.